AI assistant
Oramed Pharmaceuticals Inc. Major Shareholding Notification 2020
6965_rns_2020-01-15_7eb583dc-e19b-421f-99f3-b9d47a080c22.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| * 1. Name and Address of Reporting Person Sank Leonard |
2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] |
X | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director |
10% Owner | |||
|---|---|---|---|---|---|---|---|
| (Last) 3 BLAIR ROAD |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title below) |
Other (specify below) |
||
| (Street) CAPE TOWN (City) |
T3 (State) |
8005 (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
Person | 6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | Reported Transaction(s) (Instr. 3 and 4) |
(Instr. 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 20,000 | (1) | 01/08/2030 | Common Stock |
20,000 | \$0 | 20,000 | D |
Explanation of Responses:
- The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.
/s/ Leonard Sank 01/14/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| * 1. Name and Address of Reporting Person Mayer Arie |
2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] |
X | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director |
10% Owner | |||
|---|---|---|---|---|---|---|---|
| (Last) 16 MORAN STREET |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title below) |
Other (specify below) |
||
| (Street) KFAR SABA (City) |
L3 (State) |
4428890 (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | Reported Transaction(s) (Instr. 3 and 4) |
(Instr. 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 20,000 | (1) | 01/08/2030 | Common Stock |
20,000 | \$0 | 20,000 | D |
Explanation of Responses:
- The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020; and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.
/s/ Arie Mayer 01/14/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| * 1. Name and Address of Reporting Person Xiaoming Gao |
2. Issuer Name and Ticker or Trading Symbol ORAMED ORMP ] |
PHARMACEUTICALS | INC. [ |
X | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director |
10% Owner | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Last) | (First) 11F. NO. 266 HANKOU ROAD |
3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title below) |
below) | Other (specify | |||||||
| HUANGPU DISTRICT | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) |
||||||||||
| (Street) | X | Form filed by One Reporting Person | ||||||||||
| SHANGHAI | F4 | 2000001 | Form filed by More than One Reporting Person |
|||||||||
| (City) | (State) | (Zip) | ||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||||
| 1. Title of Security (Instr. 3) Date |
2. Transaction (Month/Day/Year) |
2A. Deemed Execution Date, if any |
3. Transaction Code (Instr. |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially |
6. Ownership Form: Direct (D) or Indirect |
7. Nature of Indirect Beneficial |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
8)
Code V Amount
(A) or (D)
Price
(Month/Day/Year)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 20,000 | (1) | 01/08/2030 | Common Stock |
20,000 | \$0 | 20,000 | D |
Explanation of Responses:
- The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.
/s/ Xiaoming Gao 01/14/2020
Owned Following Reported Transaction(s) (Instr. 3 and 4)
(I) (Instr. 4)
Ownership (Instr. 4)
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| * 1. Name and Address of Reporting Person RAKIN KEVIN |
2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] |
X | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director |
10% Owner | ||
|---|---|---|---|---|---|---|
| (Last) 36 CHURCH LANE |
(First) (Middle) |
3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title below) |
Other (specify below) |
||
| (Street) WESTPORT (City) |
CT (State) |
06880 (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | Reported Transaction(s) (Instr. 3 and 4) |
(Instr. 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. 8) |
5. Number Transaction of Code (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 20,000 | (1) | 01/08/2030 | Common Stock |
20,000 | \$0 | 20,000 | D |
Explanation of Responses:
- The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.
/s/ Kevin Rakin 01/14/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person Kidron Miriam |
* | 2. Issuer Name and Ticker or Trading Symbol ORAMED |
PHARMACEUTICALS | INC. [ |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORMP ] | X | Director | 10% Owner | ||||||||||
| (Last) (First) 2 ELZA STREET |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
X | Officer (give title below) |
below) Chief Scientific Officer |
Other (specify | |||||||
| (Street) JERUSALEM L3 (City) |
93706 (State) (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |
|||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | |||||||||||||
| 1. Title of Security (Instr. 3) 2. Transaction |
2A. Deemed 3. 4. Securities Acquired (A) or |
5. Amount of | 6. Ownership | 7. Nature |
| Date (Month/Day/Year) |
Execution Date, if any |
Transaction Code (Instr. |
Disposed Of (D) (Instr. 3, 4 and 5) |
Securities Beneficially |
Form: Direct (D) or Indirect |
of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | 8) | Owned Following Reported |
(I) (Instr. 4) | Ownership (Instr. 4) |
|||||
| V | Amount | (A) or (D) |
Price | Transaction(s) (Instr. 3 and 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
Transaction(s) (Instr. 4) |
|||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 100,000 | (1) | 01/08/2030 | Common Stock |
100,000 | \$0 | 100,000 | D |
Explanation of Responses:
- The Stock Option will vest in 4 installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
/s/ Miriam Kidron 01/14/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person KIDRON |
NADAV | ORMP ] | 2. Issuer Name and Ticker or Trading Symbol ORAMED |
PHARMACEUTICALS INC. |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X X Director 10% Owner |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Last) 142 W. 57TH ST. |
(First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title X below) |
below) President and CEO |
Other (specify | ||||||
| (Street) NEW YORK (City) |
NY (State) |
10019 (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |
|||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||||
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) Code |
V | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) Amount |
(A) or | Price | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr. 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
Transaction(s) (Instr. 4) |
|||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 190,000 | (1) | 01/08/2030 | Common Stock |
190,000 | \$0 | 190,000 | D |
Explanation of Responses:
- The Stock Option will vest in 4 installments as follows: 47,500 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
/s/ Nadav Kidron 01/14/2020
(D)
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
(Instr. 3 and 4)
Washington, D.C. 20549
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person Friedman Aviad |
* | 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ] |
X | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director |
10% Owner |
|---|---|---|---|---|---|
| (Last) (First) 6 HADASSA ST. |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/08/2020 |
Officer (give title below) |
Other (specify below) |
|
| (Street) TEL-AVIV L3 (City) (State) |
6451306 (Zip) |
4. If Amendment, Date of Original Filed (Month/Day/Year) | Line) X |
6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any (Month/Day/Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
7. Nature of Indirect Beneficial Ownership |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | Reported Transaction(s) (Instr. 3 and 4) |
(Instr. 4) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Stock Option (right to buy) |
\$4.8 | 01/08/2020 | A | 20,000 | (1) | 01/08/2030 | Common Stock |
20,000 | \$0 | 20,000 | D |
Explanation of Responses:
- The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022.
/s/ Aviad Friedman 01/14/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.